Both in clinical practice and in drug trials, combination treatment of hypertension plays a fundamental role. This article reviews the features that make combined therapy with two drugs valuable, i.e., additive antihypertensive efficacy, different mechanisms of action, and reciprocal side-effect minimization. Also examined are the advantages and disadvantages of a fixed combination, emphasizing that a major advantage is simplification of the treatment schedule. This is clinically relevant because complexity of treatment negatively affects patient compliance, which in hypertensive patients is poor, leading to poor long-term blood pressure control in the hypertensive fraction of the population.

Mancia, G., Failla, M., Grappiolo, A., Giannattasio, C. (1998). Present and future role of combination treatment in hypertension. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 31(2), S41-S44 [10.1097/00005344-199800002-00007].

Present and future role of combination treatment in hypertension

MANCIA, GIUSEPPE
Primo
;
FAILLA, MONICA
Secondo
;
GIANNATTASIO, CRISTINA
Ultimo
1998

Abstract

Both in clinical practice and in drug trials, combination treatment of hypertension plays a fundamental role. This article reviews the features that make combined therapy with two drugs valuable, i.e., additive antihypertensive efficacy, different mechanisms of action, and reciprocal side-effect minimization. Also examined are the advantages and disadvantages of a fixed combination, emphasizing that a major advantage is simplification of the treatment schedule. This is clinically relevant because complexity of treatment negatively affects patient compliance, which in hypertensive patients is poor, leading to poor long-term blood pressure control in the hypertensive fraction of the population.
Articolo in rivista - Articolo scientifico
Drug Therapy, Combination; Humans; Hypertension; Patient Compliance
English
1998
31
2
S41
S44
none
Mancia, G., Failla, M., Grappiolo, A., Giannattasio, C. (1998). Present and future role of combination treatment in hypertension. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 31(2), S41-S44 [10.1097/00005344-199800002-00007].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/59491
Citazioni
  • Scopus 12
  • ???jsp.display-item.citation.isi??? ND
Social impact